Myriad and SOPHiA GENETICS Collaborate on Liquid Biopsy Diagnostic

Myriad Genetics and SOPHiA GENETICS have announced a strategic collaboration to develop an innovative global liquid biopsy companion diagnostic (CDx) test, announced in a press release. This partnership aims to provide pharmaceutical companies with advanced diagnostic solutions by combining Myriad's laboratory capabilities in the U.S. with SOPHiA's extensive network of over 800 institutions across more than 70 countries.

The collaboration will initially focus on the liquid biopsy application, MSK-ACCESS®, powered by SOPHiA DDM™. This test, developed in collaboration with Memorial Sloan Kettering Cancer Center, detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA (ctDNA). The goal is to expand access to this high-quality tumor profiling test, thereby advancing personalized healthcare.

Myriad will handle regulatory submissions in the U.S., while SOPHiA GENETICS will manage submissions outside the U.S. Both companies will work together on development activities, aiming to provide pharmaceutical partners with access to key regulated markets globally.